[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-organ-dysfunction-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-organ-dysfunction-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,82,97,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633860","efferon-lps-hemoadsorption-in-cardiac-surgery-patients-100633860",false,"NCT07532174","Efferon LPS Hemoadsorption in Cardiac Surgery Patients","Intraoperative and Early Postoperative Use of Lipopolysaccharide Adsorption (Efferon LPS) in Cardiac Surgery Patients to Reduce the Incidence of Multiple Organ Dysfunction Syndrome in the Postoperative Period","Inclusion Criteria:\n\n* Adult patients undergoing elective or emergency cardiac surgery with the use of cardiopulmonary bypass (CPB).\n* EuroSCORE II ≥6%\n\nExclusion Criteria:\n\n* Procalcitonin ≥2 ng\u002FmL\n* Severe chronic liver disease, defined as Child-Pugh class C (\\>10 points) or clinically manifest hepatic failure\n* Dialysis-dependent chronic kidney disease (CKD)\n* Ongoing immunosuppressive therapy, including corticosteroids or cytotoxic agents, excluding standard perioperative medications\n* Any other clinical condition that, in the investigator's opinion, would preclude the patient's participation in the study","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoadsorption sessions: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.",[26,27],"Cardiac Disease","Multiple Organ Dysfunction Syndrome",[29,30,31,32],"Hemoadsorption","Hemoperfusion","Extracorporeal therapy","LPS adsorption","RECRUITING","2026-04-09",{"date":36,"type":37},"2026-04-15","ACTUAL",{"date":36,"type":20},{"date":40,"type":20},"2028-01-31",{"name":42,"class":43},"Efferon JSC","INDUSTRY",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":44},"100612144","surgical-critical-care-initiative-sc2i-tissue-and-data-acquisition-protocol-tdap-in-burn-patients-improving-the-robustness-and-generalizability-of-post-burn-sepsis-prediction-with-the-post-burn-sepsis-digital-twin-group-1-100612144","NCT07249762","Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1","Inclusion Criteria:\n\n* Burn Injury \\>10% TBSA with who have a recognized concurrent or impending risk for clinical decompensation.\n* Male and female ages 18 years and older (maximum age of 80 years old) with burn injury or related illness requiring surgical care or treatment in a critical care or emergency setting who are being cared for at an SC2i-member clinical care facility (Emory\u002FGrady, USF and USAISR) will be considered for study.\n* Ability to understand the purposes and risks of the study and to provide informed consent, either through written documentation or in accordance with the IRB-approved Waiver of Documentation of Consent procedures. In the case of incapacitated patients, a willing Legally Authorized Representative (LAR) may provide informed consent in accordance with written documentation or under the provisions of the approved Waiver of Documentation of Consent.\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the attending physician, would place the patient or volunteer subject at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, or technical considerations that would prevent acquisition of sufficient tissue for clinical use.\n* Pregnant patients\n* Minors \\\u003C 18 years of age\n* Prisoners","80 Years",{"count":53,"type":20},40,"OBSERVATIONAL","This study is following adult patients with serious burn injuries to better understand how their bodies respond to treatment and recovery. Researchers will collect small amounts of blood and tissue samples, along with information already recorded in the medical record, such as vital signs, lab results, and details of surgeries or complications. The goal is to identify patterns that may help predict who is at higher risk for infections or other problems after a burn injury. This information could lead to new tools, including computer-based models, to improve burn care and outcomes in the future. Participation involves providing samples and allowing researchers to review medical records during the hospital stay and up to one year after discharge.",[57,58,59,60,27],"Sepsis","Burn Injury","Wound Healing","Critical Illness",[62,57,60,63,64,65,66,59,67,68,69,70],"Burn Infection","Thermal Injury","Infection","Multiple Organ Dysfunction Syndrome (MODS)","Acute Respiratory Distress Syndrome (ARDS)","Biomarkers","Digital Twin Model","Predictive Analytics","Surgical Critical Care","NOT_YET_RECRUITING","2026-02-02",{"date":74,"type":37},"2026-02-04",{"date":76,"type":20},"2026-05-15",{"date":78,"type":20},"2027-12-15",{"name":80,"class":81},"Henry M. Jackson Foundation for the Advancement of Military Medicine","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":89,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":91,"keywords":92,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":96,"locationsCount":44},"100610138","tdap-in-burn-patients-group-2-100610138","NCT07223684","TDAP in Burn Patients (Group 2)","Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-Burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin","Inclusion Criteria:\n\n* Male and female ages 18 years and older (maximum age of 80 years old) with burn injury or related illness requiring surgical care or treatment in a critical care or emergency setting who are being cared for at an SC2i-member clinical care facility (Emory\u002FGrady, USF and USAISR) will be considered for study.\n* Burn Injury \\>10% TBSA\n* Ability to understand the purposes and risks of the study and willingly give written informed consent, or in the case of incapacitated patients, a willing legally authorized representative (LAR) is able to give written informed consent.\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the attending physician, would place the patient or volunteer subject at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, or technical considerations that would prevent acquisition of sufficient tissue for clinical use.\n* Pregnant patients\n* Minors \\\u003C 18 years of age\n* Prisoners",{"count":90,"type":20},80,[57,58,59,60,27],[62,57,60,63,64,65,66,59,67,68,69,70],{"date":74,"type":37},{"date":76,"type":20},{"date":78,"type":20},{"name":80,"class":81},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":107,"studyType":54,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100620157","mechanisms-of-prognostic-regulation-andprecision-phenotype-ldentification-in-severe-infections-driven-by-specializedpro-resolving-mediators-100620157","NCT07353970","Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro-Resolving Mediators","MPR-PPI-SPMs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to the intensive care unit (ICU)\n* Diagnosis of severe infection or sepsis, as determined by the treating physician according to current clinical criteria\n* Ability to obtain blood samples as part of routine clinical care within 24-48 hours after ICU admission\n* Informed consent provided by the patient or legally authorized representative (when applicable)\n\nExclusion Criteria:\n\n* Known pregnancy\n* Known immunosuppressive disease (e.g., hematologic malignancy, advanced HIV infection)\n* Use of long-term immunosuppressive therapy or systemic corticosteroids prior to ICU admission\n* Pre-existing end-stage disease with expected survival \\\u003C 28 days (e.g., end-stage cancer receiving palliative care)\n* Enrollment in interventional clinical trials that may influence immune or inflammatory responses\n* Refusal of informed consent by the patient or legal representative\n* Patients in whom blood sampling or follow-up is not feasible (e.g., expected transfer, withdrawal of life-sustaining treatment within 24 hours)","100 Years",{"count":106,"type":20},300,"28 Days","This is a prospective observational study involving adult patients with severe infection who are admitted to the intensive care unit (ICU). Severe infection and sepsis are major causes of death worldwide. Many patients experience uncontrolled inflammation or immune suppression, but current tests are limited in identifying which patients are at highest risk.\n\nThis study focuses on specialized pro-resolving mediators (SPMs), a group of naturally occurring lipid molecules that help the body turn off inflammation and promote healing. Blood samples that are collected during routine clinical care will be used to measure levels of SPMs. No additional blood draws or experimental treatments will be performed.\n\nThe purpose of this study is to understand how SPM levels change over time in patients with severe infection and how these changes relate to organ function and outcomes such as survival. By combining SPM measurements with routine laboratory results, immune cell counts, and imaging findings, the study aims to identify different clinical phenotypes and to develop tools that may help doctors recognize high-risk patients earlier in the future.\n\nAll participants will receive standard medical care determined by their treating physicians. No experimental drugs or interventions are given as part of this study.",[57,110,27,60],"Severe Infection",[112,113,114,115,116,117],"Specialized pro-resolving mediators","SPM","Resolvin D1","Immune resolution","Inflammation resolution","Critical care","2026-01-19",{"date":120,"type":37},"2026-01-21",{"date":122,"type":20},"2026-01-15",{"date":124,"type":20},"2028-01-16",{"name":126,"class":81},"Second Affiliated Hospital of Wenzhou Medical University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":135,"type":20},450,[23],"The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,27,154,155,156,157,158,159,160,161,162,163,164],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Functional Dysphonia","Constipation","Clostridium Difficile Infection","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Carbapenem-Resistant Enterobacteriaceae Infection","Vancomycin Resistant Enterococci Infection","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Alopecia","Autism","Graft-versus-host Disease","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Liver Disease","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":167,"type":37},"2024-08-22",{"date":169,"type":37},"2019-07-15",{"date":171,"type":20},"2030-10-31",{"name":173,"class":81},"Chinese University of Hong Kong",1]